Browsing tag:

antipsychotic


The USFDA has received the Aripiprazole Lauroxil NDA, submitted by Ireland-based Alkermes for treating patients with schizophrenia. Alkermes shares gained almost 2.3% on the news. Aripiprazole lauroxil is a partial dopamine agonist of the second generation class of antipsychotics, with one-month and two-month formulations, developed for the treatment of the mental disorder schizophrenia, which is[…]

Read More

As a blockbuster medication used to treat schizophrenia, Aripiprazole CAS# 129722-12-9 has recently been approved by the FDA as a once a month treatment. Marketed by Otsuka and Bristol-Myers Squibb, this monthly dosage of aripiprazole will be sold under the name Abilify Maintena. Aripiprazole is a solid and reliable long-acting antipsychotic medication, and this FDA[…]

Read More

Lurasidone CAS# 367514-87-2, is an atypical antipsychotic medication. Also known as the brand name Latuda, lurasidone is an effectual treatment for the symptoms of schizophrenia. As a second generation antipsychotic, or SGA, lurasidone is available in 20, 40, 80 and 120 milligram tablets. Latuda was approved by the FDA in October of 2010 for the[…]

Read More

Asenapine, also known as Saphris, marketed by Merck, is an efficacious drug for patients suffering from schizophrenia and bipolar disorder. Classified as an antipsychotic medication, Asenapine, CAS# 65576-45-6 is available in sublingual tablets of 5 and 10 milligrams. With the patent of Saphris expiring on June 8, 2015, a generic form of this lifesaving drug[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service